>
pdufa.bio

SLS009 (tambiciclib)

Updated ยทnext FDA decision on the calendar

SLS009 (tambiciclib) is a SELLAS Life Sciences Group, Inc. program. Its next catalyst is a Readout in Q4 2026. Every date links its source.

SLS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: SELLAS Life Sciences Group, Inc. (SLS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026SLS

Questions

When is SLS009 (tambiciclib)'s next FDA decision or readout?

The next tracked catalyst for SLS009 (tambiciclib) is a Readout in Q4 2026.

What happened at SLS009 (tambiciclib)'s most recent FDA decision?

No FDA decision for SLS009 (tambiciclib) is in our archive yet.

Who makes SLS009 (tambiciclib)?

SELLAS Life Sciences Group, Inc. (SLS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.